Synthesis of Novel Iso-4'-thionucleosides Using the Mitsunobu

Publication Date (Web): September 12, 1998 ... A novel class of isomeric 4'-thionucleosides with the base moiety at the 2'-position was synthesized fr...
55 downloads 0 Views 131KB Size
Download PDF
J. Org. Chem. 1998, 63, 6891-6899

6891

Synthesis of Novel Iso-4′-thionucleosides Using the Mitsunobu Reaction Kohei Yamada, Shinji Sakata, and Yuichi Yoshimura*,† Biochemicals Division, Yamasa Corporation, 2-10-1 Araoicho, Choshi, Chiba 288-0056, Japan Received April 10, 1998

A novel class of isomeric 4′-thionucleosides with the base moiety at the 2′-position was synthesized from D-glucose. The coupling of 1,4-anhydro-4-thioarabitol (13) with various nucleobases using the Mitsunobu reaction was investigated. With both purines and N 3-benzoyluracils, the reaction predominantly gave β-isomers, suggesting that these were produced via an episulfonium intermediate. The β-anomers produced by the reaction of N 3-benzoyluracils included both N- and O-alkylated derivatives. Interestingly, only the reaction of N 3-benzoyluracil gave a mixture of N-alkylated adduct (20d) and O-alkylated bipyrimidinyl adduct (22), the structure of which was unambiguously determined by NMR spectroscopic data including HMBC and NOE. Deprotection of the Mitsunobu reaction products gave the desired iso-4′-thionucleosides. Introduction New compounds that are effective against human immunodeficiency virus (HIV), a causative agent of acquired immunodeficiency syndrome (AIDS), are urgently required. Nucleoside analogues, most of which act as inhibitors of reverse transcriptase (RT) coded by HIV, play an important role in the treatment of AIDS. To date, five nucleoside RT inhibitors, including some dideoxynucleosides (ddC, ddI, d4T), have been approved for clinical use. However, such dideoxynucleosides have shown limited stability: the glycosidic linkage of dideoxynucleosides is susceptible to both acidic and enzymatic hydrolysis. To circumvent this problem, a new class of dideoxynucleosides, isonucleosides (1: R ) H; Chart 1), in which the base moiety is transposed from the natural 1′- to the 2′-position, were synthesized and shown to have potent anti-HIV activity and to be stable against hydrolysis of the glycosidic bond.1 In addition to being antiHIV agents, Tino2 and Matsuda3 independently reported that isonucleosides (2, R ) OH; 3, R ) CH2OH) had antiherpes virus and -hepatitis B virus (HBV) activity. A new anti-HIV dideoxynucleoside, 2′-deoxy-3′-thiacytidine4 (3TC, 4), which has been used for the treatment of AIDS in clinical fields, has unique structural features: it is a synthetic L-nucleoside with an oxathiolane † Tel: 479-22-0095 ext. 384. Fax: 479-22-9821. E-mail: [email protected]. (1) (a) Huryn, D. M.; Sluboski, B. C.; Tam, S. Y.; Weigele, M.; Sim, I.; Anderson, B. D.; Mitsuya, H.; Broder, S. J. Med. Chem. 1992, 35, 2347. (b) Nair, V.; Nuesca, Z. M. J. Am. Chem. Soc. 1992, 114, 7951. (2) Tino, J. A.; Clark, J. M.; Kirk Field, A.; Jacobs, G. A.; Lis, K. A.; Michalik, T. L.; McGeever-Rubin, B.; Slusarchyk, W. A.; Spergel, S. H.; Sundeen, J. E.; Tuomari, A. V.; Weaver, E. R.; Young, M. G.; Zahler, R. J. Med. Chem. 1993, 36, 1221. (3) Kakefuda, A.; Shuto, S.; Nagahata, T.; Seki, J.; Sasaki, T.; Matsuda, A. Tetrahedron 1994, 50, 10167. (4) (a) Schinazi, R. F.; Chu, C. K.; Peck, A.; McMillan, A.; Mathis, R.; Cannon, D.; Jeong, L.-S.; Beach, J. W.; Choi, W.-B.; Yeola, S.; Liotta, D. C. Antimicrob. Agents Chemother. 1992, 36, 672. (b) Coates, J. A. V.; Cammack, N.; Jenkinson, H. J.; Jowett, A. J.; Jowett, M. I.; Pearson, B. A.; Penn, C. R.; Rouse, P. L.; Viner, K. C.; Cameron, J. M. Antimicrob. Agents Chemother. 1992, 36, 733. (c) Poong, S.-L.; Tsai, C.-H.; Schinazi, R. F.; Liotta, D. C.; Chen, Y.-C. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8495. (d) Beach, J. W.; Jeong, L.-S.; Alves, A. J.; Pohl, D.; Kim, H. O.; Chang, C.-N.; Doong, S.-L.; Schinazi, R. F.; Cheng, Y.-C.; Chu, C. K. J. Org. Chem. 1992, 57, 2217.

Chart 1

skeleton. From another perspective, 3TC is similar to 2′-isomeric-3′-oxo-4′-thio-β-D-cytidine or belongs to a novel class of iso-4′-thionucleosides. Thus, iso-4′-thionucleosides may be promising candidates as anti-HIV agents. However, despite such attractive structural features, there are few reports concerning iso-4′-thionucleosides.5 This prompted us to design iso-4′-thionucleosides (6) as a hybrid constructive analogue of 2′-deoxynucleosides and 3TC. Recently, we developed a new route to the synthesis of 4′-thionucleosides (5) with 2′-substituents,6 and this may be applicable to the preparation of iso-4′-thionucleosides (6), using the same chiral synthon, 1,4-anhydro-4thio-D-arabitol derivatives (7), as a starting material. We expected that it would be possible to introduce nucleobases at the 2-position of 7 with an “up” configuration, when the direct substitution reaction of the hydroxyl group proceeds with a retention of configuration. It has (5) Jones, M. F.; Noble, S. A.; Robertson, C. A.; Storer, R. Tetrahedron Lett. 1991, 32, 247. (6) (a) Yoshimura, Y.; Kitano, K.; Satoh, H.; Watanabe, M.; Miura, S.; Sakata, S.; Sasaki, T.; Matsuda, A. J. Org. Chem. 1996, 61, 822. (b) Yoshimura, Y.; Kitano, K.; Yamada, K.; Satoh, H.; Watanabe, M.; Miura, S.; Sakata, S.; Sasaki, T.; Matsuda, A. J. Org. Chem. 1997, 62, 3140. (c) Yoshimura, Y.; Watanabe, M.; Satoh, H.; Ashida, N.; Ijichi, K.; Sakata, S.; Machida, H.; Matsuda, A. J. Med. Chem. 1997, 40, 2177.

S0022-3263(98)00667-7 CCC: $15.00 © 1998 American Chemical Society Published on Web 09/12/1998

6892 J. Org. Chem., Vol. 63, No. 20, 1998

Yamada et al. Scheme 1

been reported that some SN2-type reactions at the β-position to the sulfur atom of tetrahydrothiopyran and tetrahydrothiophene derivatives proceeded with retention of configuration because of the formation of episulfonium intermediates.7 This finding encouraged us to use the Mitsunobu reaction8 to introduce nucleobases with an “up” configuration. In this report, we describe the coupling reaction of 1,4-anhydro-4-thio-D-arabitol derivative (7) with various nucleobases using the Mitsunobu reaction and the synthesis of iso-4′-thionucleosides.

Scheme 2

Results and Discussion We intended to use the Mitsunobu reaction to introduce nucleobases into the 2-position of 1,4-anhydro-4thio-D-arabitol (7), which was readily obtained from D-glucose, as we reported previously.6 If the Mitsunobu reaction proceeded via an episulfonium cation (9), as depicted in Scheme 1, the nucleobase moiety could be introduced at the 2-position with high β-stereoselectivity. Initially, a coupling reaction of 3-O-benzyl derivative 13 with 6-chloropurine in THF was examined.9,10 This reaction gave a mixture of two diastereoisomers11 in 29% yield (β/R ) 1.1; see Table 1, entry 1). This result showed that the episulfonium intermediate (9), which gave rise to the formation of β-isomer, might compete with a direct SN2 reaction (Scheme 1). In addition, thietane derivatives (12), which would be formed by nucleophilic attack at the 1-position of 9, were not found in the reaction mixture. This also showed that nucleophilic ring-opening of the episulfonium cation (9) would take place regioselectively, controlled by the thermodynamic stability of the products.7b (7) (a) Jeong, L.-S.; Nicklaus, M. C.; George, C.; Marquez, V. E. Tetrahedron Lett. 1994, 35, 7573. (b) Recently, it has been reported that the Mitsunobu reaction of tetrahydrothiopyran derivatives with benzoic acid proceeded with retention of configuration and was associated with the formation of the benzoated tetrahydrothiophen as a minor product: Fuzier, M.; Merrer, Y. L.; Depezay J.-C. Tetrahedron Lett. 1995, 36, 6443. (8) Mitsunobu, O. Synthesis 1981, 1. (9) The Mitsunobu reaction of the 3-O-benzoyl derivative, instead of 13, with 6-chloropurine gave an undesired R-isonucleoside, stereoselectively, the stereochemistry of which was determined by NOE experiments. This result suggests that the more electron-withdrawing benzoyl group at the 3-position makes the carbon at the 2-position electron deficient, thus potentiating the external nucleophilic attack. (10) Contrary to our expectation, when tributylphosphine was used instead of triphenylphosphine, the reaction was not complete in THF at 50 °C even after 44 h. Only R-14a was obtained in 11% yield with a recovery of 13 in 32% yield. (11) The undesired N7-adduct of 6-chloropurine was not obtained. Similarly, none of the N7-adducts were found in the reaction of the other purine bases. The structure of N9-adducts were confirmed by UV spectra after being converted to the deblocked compounds.

Table 1. Mitsunobu Reaction of 1,4-Anhydro-4-thio-D-arabitol Derivatives (13) with Purine Bases entry

purine base

solvent

product

1 2 3 4 5 6 7 8 9 10 11

X1 ) Cl, X2 ) H X1 ) Cl, X2 ) H X1 ) Cl, X2 ) H X1 ) Cl, X2 ) H X1 ) Cl, X2 ) H X1 ) Cl, X2 ) H X1 ) Cl, X2 ) NH2 X1 ) X2 ) NH2 X1 ) Cl, X2 ) NHAc X1 ) X2 ) NHAc X1 ) X2 ) Cl

THFa THFb benzenea CH3CNa CH2Cl2a DMFc THFc THFc THFa THFa THFa

14a 14a 14a 14a 14a 14a

a

14b 14c

yield (%)d

β/R ratio

29 24 34 21 22 trace NR NR 38 NR 33

1.1e 1.4e 0.8e 6.0e 1.2e

1.8f 3.1e

b

Reaction was carried out at room temperature. Reaction was carried out at 50 °C. c Reaction was carried out at 70 °C. d Isolated yields. e Isolated yields of two isomers. f β/R ratio was determined by 1H NMR analysis.

On the other hand, we also attempted to react 6-chloropurine with a 2-O-mesylate of 13 in the presence of K2CO3 and 18-crown-6 in DMF. However, the formation of negligible amount of iso-4′-thionucleoside could only be observed even at the reflux temperature (data not shown). Thus, we tried to investigate the Mitsunobu coupling reaction of 3-O-benzyl derivative (13) with various purine bases in an appropriate solvent. The results are summarized in Table 1. The β-isomer was predominant (β/R ) 6.0) when acetonitrile was used; however, there was no improvement in the yield of 14a (entry 4). In a previous report, the Mitsunobu reaction of 13 with diphenylphosphoryl azide gave a ribo-azide derivative, suggesting that a direct SN2 reaction of azide anion, without the participation of episulfonium ion, had occurred from the R-side.6b In contrast, the same Mitsunobu reaction with 6-chloropurine gave predominantly the β-isomer or a mixture of R- and β-isomers. These results can be explained in terms of the potency of their

Iso-4′-thionucleosides

J. Org. Chem., Vol. 63, No. 20, 1998 6893

nucleophilicities. The nucleophilic reaction of azide anion is faster than the formation of the strained episulfonium cation and, thus, proceeds via direct SN2 reaction with inversion.6b On the other hand, the weak nucleophilicity of 6-chloropurine makes the formation of episulfonium cation energetically favorable. As a result, the reaction proceeds via competition between a direct SN2 reaction and an episulfonium intermediate. In more polar acetonitrile, the latter path would be favored. In the case of 2,6-dichloropurine, a similar result was obtained (33% yield, β/R ) 3.1, entry 11). The R,βisomers (14a,c) could be easily separated on a silica gel column. On the other hand, the reactions with 2,6diaminopurine or 2-amino-6-chloropurine did not proceed at all because they were scarcely soluble in THF (entries 7 and 8).12 Accordingly, the reaction of 2-(acetylamino)6-chloropurine gave 14b in 38% yield, as an inseparable mixture of R,β-isomers (β/R ) 1.8, entry 9), which could be successfully separated in the next step. The assignment of R- and β-stereochemistry was confirmed by NOE experiments. As shown in Figure 1, irradiation of H-2′ and H-3′ of β-14a enhanced the H-4′ and H-8 protons by 6.5% and 2.7%, respectively. The stereochemistry of β-17 was also confirmed by 1H NMR in comparison with the chemical shift of the H-2′ proton13 of the corresponding R-17 (data not shown). The Mitsunobu adducts 14a,b were converted to their corresponding adenine and guanine iso-4′-thionucleosides, as shown in Scheme 3. The benzyl group of the desirable β-isomer of 14a was effectively removed by treatment with boron trichloride (BCl3) in dichloromethane at -78 °C. Subsequently, compound β-15 was desilylated by ammonium hydrogen fluoride in methanol and converted into iso-4′-thioadenosine β-16 by amination of the 6-position with ethanolic ammonia. Likewise, the 2,6diaminopurine derivative β-18 and guanine derivative β-19 were prepared. Debenzylation of a mixture of Rand β-isomers of 14b under the conditions described above gave only the deprotected β-isomer (β-17) in 32% yield with unreacted R-isomer (R-14b) recovered in 8% yield. Although the R- and β-isomers of 14b were effectively separated, the yields were relatively low. This is presumably due to complexation of the products with borane. However, attempts to recover further β-14b from the complex were not successful. The desirable β-isomer of 17 was desilylated and then converted into 2,6diaminopurine derivative β-18 by treatment with aqueous ammonia in methanol. In addition, guanine derivative β-19 was synthesized by acidic hydrolysis of the 6-chloro moiety of β-17 and subsequent deacetylation.

Next, we tried to prepare pyrimidine analogues using the above-mentioned reaction. In contrast to purine bases, the reaction with N 3-benzoyluracil derivatives14 hardly proceeded at room temperature. However, the reaction at 70 °C gave pyrimidine isonucleosides in moderate yields. In the case of pyrimidine bases, a mixture of four isomers (R- and β-isomers of N-/Oalkylated derivatives) was produced, and these were difficult to separate. Fortunately, the R-isomers of the N-and O-alkyl compounds were not detected when acetonitrile was used as a solvent (e.g., R/β ratio of N-alkyl5-fluorouracil derivative 20a: R, 7%, and β, 11%, in THF vs R, ∼0%, and β, 18%, in acetonitrile). However, the reaction did not proceed regioselectively, and the product contained a mixture of N- and O-alkylated uracil (N/O ratio ) 1.2-2.3), as shown in Table 2. These regioisomers could not be separated at this step on a silica gel column, with the exception of 5-fluorouracil derivative 20a. Interestingly, only the reaction of N 3-benzoyluracil (R3 ) H) gave an N-alkylated product 20d along with O-alkylated compound 22, whose structure was unknown and determined later (vide infra). As shown in Scheme 5, the desired N-alkylated 5-fluorouracil derivative 23a was obtained in 91% yield by the debenzoylation of the N-alkyl-5-fluorouracil 20a. Similarly, deprotection of the mixture of N,O-alkyl-5-methyluracil 20b/21b and (E)-5-(bromovinyl)uracil 20c/21c gave desired N-alkyluracils in yields of 46% and 59%, respectively. These were easily separated from their O-alkyluracils on a silica gel column at this step. Removal of the benzyl group and subsequent desilylation gave 5-fluorouracil 25a, 5-methyluracil 25b, and (E)-5-(bromovinyl)uracil derivative 25c in yields of 85%, 74%, and 71%, respectively. Assignment of N,O-regio- and R,β-stereochemistry was strictly determined on the basis of 1H NMR and NOE spectra. For example, as shown in Figure 2, irradiation of H-3′ and H-2′ of N-alkyl compound 23b enhanced the H-6 and H-4′ protons by 8.1% and 5.2%, respectively. In contrast, irradiation of H-4′ of O-alkyl compound 24b enhanced the H-2′ proton by 2.5%, while irradiation of H-3′ did not enhance the H-6 proton. It has been reported that the resonance of the H-2′ proton in O-alkyl compounds shifted downfield compared with that in N-alkyl compounds.3 This held true for all of the iso-4′thionucleosides that we synthesized. Furthermore, as shown in Scheme 6, the mixture of N,O-alkyl uracil 20d/22 was debenzoylated and aminated at the 4-position by treatment with 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl) in acetonitrile in the presence of triethylamine and 4-(dimethylamino)pyridine (DMAP), followed by aqueous ammonia, to give cytosine derivative 27 in 55% yield as a mixture with O-alkyl compound 28. Treatment of 27/28 with BCl3 at -78 °C gave 29 in 53% yield, which was successfully separated from O-alkyl compound 30. Finally, iso-4′-thiocytidine 31 was synthesized in 69% yield by desilylation using NH4F‚HF in DMF. Likewise, O-alkyl compound 30 was converted into 32 in 79% yield. The spectral analysis of 32 revealed an unexpected structure. In the 1H NMR spectrum of 32, the chemical

(12) Although the reaction mixture became clear when DMF was used as a solvent, there was also no reaction (cf. Table 1, entry 6). (13) In the 1H NMR spectra of R- and β-15, the resonance of the H-2′ proton in the β-isomer was shifted upfield compared with that in the R-isomer.

(14) (a) Kametani, T.; Kigasawa, K.; Hiiragi, M.; Wakisaka, K.; Haga, S.; Nagamatsu, Y.; Sugi, H.; Fukawa, K.; Irino, O.; Yamamoto, T.; Nishimura, N.; Taguchi, A.; Okada, T.; Nakayama, M. J. Med. Chem. 1980, 23, 1324. (b) Cruickshank, K. A.; Jiricny, J.; Reese, C. B. Tetrahedron Lett. 1984, 25, 681.

Figure 1.

6894 J. Org. Chem., Vol. 63, No. 20, 1998

Yamada et al. Scheme 3a

a Reagents and conditions: (a) BCl , CH Cl , -78 °C, 87%; (b) NH ‚HF, MeOH; (c) NH , EtOH, 80 °C, 77% from β-15; (d) BCl , CH Cl , 3 2 2 4 3 3 2 2 -78 °C, 32% (8% recovery of R-14b); (e) NH4‚HF, DMF; (f) NH4OH, MeOH, 80 °C, yield a β-18 in 66% from β-17; (g) TFA, H2O and then NH4OH, MeOH, 80 °C, yield of β-19 in 80% from β-17.

Scheme 5a

Scheme 4

a Reagents and conditions: (a) NH OH, MeOH, THF, 23a (91%), 4 24a (49%), 23b (46%), 24b (39%), 23c (59%), 24c (39%); (b) (i) BCl3, CH2Cl2, -78 °C, (ii) NH4F‚HF, DMF, 25a (85%), 25b (74%), 25c (71%), 26a (71%), 26b (77%), 26c (65%).

Table 2. Mitsunobu Reaction of 1,4-Anhydro-4-thio-D-arabitol Derivatives (13) with Pyrimidine Basesa entry

pyrimidine base

product

yield (%)b

N/O ratio

1 2 3 4

R)F R ) Me R ) (E)-bromovinyl R)H

20a/21a 20b/21b 20c/21c 20d/22

26 36 40 39

2.3c 1.3d 1.4d 1.2d

a Reaction was carried out at 70 °C. b Isolated yields. c Isolated yields of two regioisomers. d Ratio was determined by 1H NMR analysis.

shift of the H-2′ proton (5.35 ppm) suggested a 2′-O2alkylated structure. Surprisingly, two sets of protons corresponding to the 5- and 6-positions of the pyrimidine ring were observed. One of the pyrimidines showed two

Figure 2.

doublet peaks at 8.29 and 5.99 ppm (J ) 7.8 Hz). The other showed another set of doublets, which were shifted downfield, at 8.60 and 7.80 ppm (J ) 5.4 Hz). The 13C NMR spectrum of 32 also showed eight carbon peaks of two pyrimidines (see Experimental Section). These results clearly indicated that this compound had two pyrimidine moieties per molecule. This was also supported by the results of mass spectrum and elemental analysis. Moreover, the UV spectrum of 32 suggested that one pyrimidine ring combined with the other, i.e., a

Iso-4′-thionucleosides

J. Org. Chem., Vol. 63, No. 20, 1998 6895 Scheme 6a

a Reagents and conditions: (a) NH OH, MeOH, THF; (b) TPSCl, 4 Et3N, DMAP, CH3CN, and then NH4OH, 55% (27/28 ) 2.2) from 20d/22; (c) BCl3, CH2Cl2, -78 °C, 29 (53%), 30 (22%); (d) NH4F‚HF, DMF, 31 (69%), 32 (79%).

Scheme 7

the reaction of N 3-benzoyluracil gave the bipyrimidinyl compound. In summary, the coupling of 1,4-anhydro-4-thio-Darabitol (13) with various nucleobases using the Mitsunobu reaction was investigated. β-Adducts were predominantly formed when acetonitrile was used as a solvent. This result suggests that the reaction proceeded with retention of configuration via an episulfonium intermediate. This method could be effectively applied to the synthesis of iso-4′-thionucleosides. However, none of the compounds which we tested showed any antiviral activity (herpes simplex virus type 1 and type 2, varicella zoster virus, human cytomegalovirus, HIV) or cytotoxicity.15

Experimental Section

Figure 3.

4-O2′′- or 4-N 1′′-alkylated structure. Finally, its regio- (at the 2′- and 4-positions, respectively) and stereochemistry (at the 2′-position) were determined by HMBC and NOE experiments. In the HMBC spectrum of 32, a cross-peak of H-2′ to C-2 was observed, indicating a 2′-O2-alkylated compound. Furthermore, the NOE experiment of 32, in which irradiation of H-4′ enhanced the H-2′ proton by 2.3%, supported its β-stereochemistry at the 2′-position. On the other hand, a cross-peak of H-6′′ to C-4 was also observed in the HMBC spectrum. This ruled out the 4-O2′′-alkylated structure, as did the NOE experiment: irradiation of H-5 of 32 enhanced the H-6′′ proton by 2.3%. Thus, the structure of 32 was unambiguously determined, as depicted in Figure 3. The bipyrimidinyl compound seemed to be produced by an extra Mitsunobu-type reaction as shown in Scheme 7. Initially, the O-alkylated derivative 33 was produced like those of other 5-substituted uracils. The second reaction then took place at the 4-position, when aromatization of the pyrimidine ring occurred along with cleavage of the N 3-benzoyl group. Presumably, this aromatization might cause differences in the reactivities of O- and N-alkylated derivatives in the extra Mitsunobu reaction at the 4-position. Although the O2- and/or N 1anion of the extra benzoyluracil might attack the 4-position of 34, 4-N 1′′-bipyrimidinyl compound 35, in which substitution occurred at the softer N 1-site, was obtained. The 4-N 1′′-bipyrimidinyl product 35 was not attacked by further N 3-benzoyluracil. It was not obvious that only

General Methods. Melting points are uncorrected. 1H NMR spectra were recorded at 400 MHz (1H) and at 100 MHz (13C) using CDCl3 or DMSO-d6 with TMS as internal standard. Mass spectra were obtained by the fast atom bombardment (FAB) mode. Silica gel for chromatography was Merck Kieselgel 60. (2R)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-(6-chloropurin-9-yl)-2-deoxy-4-thio-D-ribitol (r14a) and (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-(6-chloropurin-9-yl)-2-deoxy-4-thio- Darabitol (β-14a). To a solution of 136a,b (1.20 g, 2.5 mmol) and triphenylphosphine (2.0 g, 7.5 mmol) in anhydrous THF (42 mL) were added 6-chloropurine (1.16 g, 7.5 mmol) and DEAD (1.2 mL, 7.5 mmol), and the mixture was stirred for 21 h at room temperature under argon. The reaction was quenched by addition of EtOH. After the solvent was evaporated under reduced pressure, the concentrated residue was purified by column chromatography over silica gel (3.6 × 19 cm, CHCl3, and then 2.5 × 30 cm, 5-30% AcOEt in hexane) to give less polar R-14a (222 mg, 14%) and more polar β-14a (228 mg, 15%) as an amorphous foam, respectively. Data for r-14a: 1H NMR (CDCl3) δ 8.66 (1H, s, H-2), 8.41 (1H, s, H-8), 7.72-7.67 (4H, m, Ar H), 7.45-7.37 (6H, m, Ar H), 7.19-7.12 (3H, m, Ar H), 7.00-6.98 (2H, m, Ar H), 5.27 (1H, ddd, H-2′, J ) 3.9, 6.8, 10.7 Hz), 4.60 (1H, d, PhCH, J ) 11.7 Hz), 4.40 (1H, d, H-3′, J ) 3.9 Hz), 4.31 (1H, d, PhCH, J ) 11.7 Hz), 3.78-3.71 (3H, m, H-4′, H-5′a,b), 3.52 (1H, t, H-1′a, J ) 10.7 Hz), 3.21 (1H, dd, H-1′b, J ) 6.8, 10.7 Hz), 1.10 (9H, s, t-Bu); FAB-MS m/z 615, 617 (M+ + H). Anal. Calcd for C33H35N4O2SSiCl‚0.25H2O: C, 63.95; H, 5.77; N, 9.04. Found: C, 63.92; H, 5.80; N, 8.83. Data for β-14a: 1H NMR (CDCl3) δ 8.59 (1H, s, H-2), 8.08 (1H, s, H-8), 7.69 (4H, dd, Ar H, J ) 1.5, 7.8 Hz), 7.47-7.37 (6H, m, Ar H), 7.09-6.99 (3H, m, Ar H), 6.80 (2H, d, Ar H, J (15) Antiviral activities, except against HIV, and cytotoxicity were assayed at the Biological Laboratory of Yamasa Corp. Anti-HIV activity was tested at the Rational Drug Design Laboratories, Fukushima, Japan. We greatly appreciate their assistance.

6896 J. Org. Chem., Vol. 63, No. 20, 1998 ) 7.8 Hz), 5.01-4.95 (1H, m, H-2′), 4.74 (1H, dd, H-3′, J ) 5.9, 8.3 Hz), 4.48 (1H, d, PhCH, J ) 11.7 Hz), 4.19 (1H, d, PhCH, J ) 11.7 Hz), 3.89 (1H, dd, H-5′a, J ) 5.9, 10.8 Hz), 3.85 (1H, dd, H-5′b, J ) 5.9, 10.8 Hz), 3.75 (1H, t, H-1′a, J ) 11.2 Hz), 3.59 (1H, q, H-4′, J ) 5.9 Hz), 3.08 (1H, dd, H-1′b, J ) 6.8, 11.2 Hz), 1.11 (9H, s, t-Bu); FAB-MS m/z 615, 617 (M+ + H). Anal. Calcd for C33H35N4O2SSiCl: C, 64.42; H, 5.73; N, 9.11. Found: C, 64.25; H, 5.90; N, 8.86. (2R)-2-(2-(Acetylamino)-6-chloropurin-9-yl)-1,4-anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4thio-D-ribitol and (2S)-2-(2-(Acetylamino)-6-chloropurin9-yl)-1,4-anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)2-deoxy-4-thio-D-arabitol (r,β-14b). Compound 13 (3.60 g, 2.84 mmol) was converted as described for the synthesis of R,β-14a to give R,β-14b (1.91 g, 38%, β/R ) 1.8, as an amorphous foam): 1H NMR (CDCl3) δ 8.28 (0.36H, s, H-2), 7.95 (0.64H, s, H-8), 7.91 (0.64H, br s, NH), 7.88 (0.36H, br s, NH), 7.69-6.80 (15H, m, Ar H), 5.12-5.05 (0.36H, m, H-2′), 4.91-4.85 (0.64H, m, H-2′), 4.60 (0.36H, d, PhCH, J ) 11.7 Hz), 4.54-4.48 (1.28H, m, PhCH, H-3′), 4.36-4.33 (0.72H, m, PhCH, H-3′), 4.22 (0.64H, d, PhCH, J ) 12.2 Hz), 4.13-3.56 (3.64, m, H-4′ × 2, H-5′a,b × 2, 1′-Ha), 3.49 (0.36H, t, H-1′a, J ) 10.3 Hz), 3.21 (0.36H, dd, H-1′b, J ) 6.3, 10.3 Hz), 3.09 (0.64H, dd, H-1′b, J ) 7.3, 11.2 Hz), 2.45 (1.92H, s, Ac), 2.44 (1.08H, s, Ac), 1.10 (9H, s, t-Bu); FAB-MS m/z 672, 674 (M+ + H). Anal. Calcd for C35H38N5O3SSiCl‚0.5H2O: C, 61.70; H, 5.77; N, 10.28. Found: C, 61.78; H, 5.74; N, 10.31. (2R)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-2-(2,6-dichloropurin-9-yl)-4-thio-D-ribitol (r-14c) and (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-2-(2,6-dichloropurin-9-yl)-4-thioD-arabitol (β-14c). Compound 13 (120 mg, 0.25 mmol) was converted as described for the synthesis of R,β-14a to give less polar R-14c (12.7 mg, 8%) and more polar β-14c (40 mg, 25%) as a colorless oil, respectively. Data for r-14c: 1H NMR (CDCl3) δ 8.31 (1H, s, H-8), 7.667.61 (4H, m, Ar H), 7.39-7.32 (6H, m, Ar H), 7.19-7.08 (3H, m, Ar H), 6.95-6.93 (2H, m, Ar H), 5.12-5.07 (1H, m, H-2′), 4.54 (1H, d, PhCH, J ) 11.7 Hz), 4.35 (1H, d, H-3′, J ) 3.9 Hz), 4.25 (1H, d, PhCH, J ) 11.7 Hz), 3.71-3.59 (3H, m, 4′H, H-5′a,b), 3.41 (1H, t, H-1′a, J ) 10.3 Hz), 3.13 (1H, dd, H-1′b, J ) 6.4, 10.3 Hz), 1.04 (9H, s, t-Bu); FAB-MS m/z 649, 651 (M+ + H). Data for β-14c: 1H NMR (CDCl3) δ 8.03 (1H, s, H-8), 7.707.68 (4H, m, Ar H), 7.47-7.39 (6H, m, Ar H), 7.07-7.01 (3H, m, Ar H), 6.87-6.85 (2H, m, Ar H), 4.93-4.87 (1H, m, H-2′), 4.63 (1H, dd, H-3′, J ) 6.3, 8.3 Hz), 4.53 (1H, d, PhCH, J ) 12.2 Hz), 4.24 (1H, d, PhCH, J ) 12.2 Hz), 3.90 (1H, dd, H-5′a, J ) 5.4, 10.7 Hz), 3.82 (1H, dd, H-5′b, J ) 5.4 Hz, 10.7 Hz), 3.63 (1H, t, H-1′a, J ) 10.7 Hz), 3.58-3.54 (1H, m, H-4′), 3.06 (1H, dd, H-1′b, J ) 6.8, 10.7 Hz), 1.12 (9H, s, t-Bu); FAB-MS m/z 649, 651 (M+ + H). (2S)-1,4-Anhydro-5-O-(tert-butyldiphenylsilyl)-2-(6-chloropurin-9-yl)-2-deoxy-4-thio-D-arabitol (β-15). To a solution of β-14a (227 mg, 0.37 mmol) in CH2Cl2 (7.5 mL), was added slowly a solution of BCl3 (3.0 mL of a 1 M CH2Cl2 solution, 3.0 mmol) at -78 °C under argon. After being stirred for 0.5 h at room temperature, the reaction was quenched by addition of pyridine-MeOH (4.5 mL, 2:1). The mixture was allowed to warm to room temperature and was stirred for 1 h. After the most of organic solvents were removed under reduced pressure, the remaining material was extracted with AcOEt (×2). The organic phase was washed with H2O and brine and then dried (Na2SO4). After the solvent was evaporated under reduced pressure, the concentrated residue was purified by column chromatography over silica gel (1.5 × 11 cm, 10-30% AcOEt in hexane) to give β-15 (169 mg, 87%) as an amorphous foam: 1H NMR (CDCl3) δ 8.65 (1H, s, H-2), 8.11 (1H, s, H-8), 7.61-7.57 (4H, m, Ar H), 7.41-7.31 (6H, m, Ar H), 4.91 (1H, dt, H-2′, J ) 7.3, 10.3 Hz), 4.70 (1H, dd, H-3′, J ) 8.3, 10.3 Hz), 3.89 (1H, dd, H-5′a, J ) 5.4, 10.3 Hz), 3.83 (1H, dd, H-5′b, J ) 7.8, 10.3 Hz), 3.53 (1H, t, H-1′a, J ) 10.3 Hz), 3.48 (1H, dt, H-4′, J ) 5.4, 8.3 Hz), 3.18 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz), 2.45-2.02 (1H, br, 3′-OH), 1.00 (9H, s, t-Bu);

Yamada et al. FAB-MS m/z 525, 527 (M+ + H). Anal. Calcd for C26H29N4O2SSiCl: C, 59.47; H, 5.57; N, 10.67. Found: C, 59.40; H, 5.72; N, 10.37. (2S)-2-(Adenin-9-yl)-1,4-anhydro-2-deoxy-4-thio-D-arabitol (β-16). A mixture of β-15 (169 mg, 0.32 mmol) and NH4F‚HF (253 mg, 4.44 mmol) in MeOH (5.5 mL) was stirred for 40 h at room temperature. After concentration, the residue was passed through a short silica gel column. The eluate with 10% MeOH in CHCl3 was collected and concentrated. The residue was dissolved in saturated methanolic ammonia (10 mL) and heated at 80 °C in a sealed tube for 20 h. After cooling, the solvent was removed under reduced pressure and the residue was purified by column chromatography over silica gel (1.5 × 5.5 cm, 1-10% MeOH in CHCl3) to give β-16 (66 mg, 77%) as crystals: mp 96 °C (dec, crystallized from MeOH); UV (MeOH) λmax 261 nm; 1H NMR (DMSO-d6) δ 8.18 (1H, s, H-2 or H-8), 8.12 (1H, s, H-2 or H-8), 7.19 (2H, br s, NH2), 5.56 (1H, d, 3′-OH, J ) 6.8 Hz), 4.92 (1H, dd, 5′-OH, J ) 4.4, 5.9 Hz), 4.81-4.74 (1H, m, H-2′), 4.43 (1H, dt, H-3′, J ) 6.8, 8.3 Hz), 3.86 (1H, dt, H-5′a, J ) 4.4, 10.8 Hz), 3.45-3.37 (1H, m, H-5′b), 3.39 (1H, t, H-1′a, J ) 10.7 Hz), 3.24 (1H, dt, H-4′, J ) 4.4, 8.3 Hz), 3.03 (1H, dd, H-1′b, J ) 7.3, 10.7 Hz); FABMS m/z 268 (M+ + H). Anal. Calcd for C10H13N5O2S‚ 0.33MeOH: C, 44.65; H, 5.20; N, 25.19. Found: C, 44.42; H, 4.96; N, 24.91. (2S)-2-(2-(Acetylamino)-6-chloropurin-9-yl)-1,4-anhydro-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (β-17). To a solution of R,β-14b (1.91 g, 2.84 mmol) in CH2Cl2 (61 mL) was added slowly a solution of BCl3 (25 mL of a 1 M CH2Cl2 solution, 25.0 mmol) at -78 °C under argon. After being stirred for 1.5 h at the same temperature, the reaction was quenched by addition of pyridine-MeOH (33 mL, 2:1). The mixture was allowed to warm to room temperature and was stirred for 1 h. After the solvents were removed under reduced pressure, the concentrated residue was purified by column chromatography over silica gel (3.4 × 16 cm, 20% MeOH in CHCl3 and then 3.4 × 10 cm, 50% AcOEt in hexane) to give β-17 (529 mg, 32%) as a white solid. Unreacted R-14b was recovered as a single isomer (145 mg, 8%): mp 180-184 °C; 1H NMR (CDCl3) δ 8.17 (1H, br s, NH), 8.14 (1H, s, H-8), 7.69-7.65 (4H, m, Ar H), 7.46-7.36 (6H, m, Ar H), 4.93-4.89 (1H, m, H-2′), 4.69 (1H, t, H-3′, J ) 8.3 Hz), 3.93 (2H, d, H-5′a,b, J ) 8.9 Hz), 3.61-3.56 (1H, m, H-4′), 3.45 (1H, t, H-1′a, J ) 10.3 Hz), 3.29 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz), 2.99-2.45 (1H, br, 3′-OH), 1.05 (9H, s, t-Bu); FAB-MS m/z 582, 584 (M+ + H). Anal. Calcd for C28H32N5O3SSiCl‚0.2hexane: C, 58.51; H, 5.85; N, 11.68. Found: C, 58.35; H, 5.80; N, 11.62. (2S)-1,4-Anhydro-2-deoxy-2-(2,6-diaminopurin-9-yl)-4thio-D-arabitol (β-18). A mixture of β-17 (46 mg, 0.08 mmol) and NH4F‚HF (54 mg, 0.95 mmol) in DMF (1 mL) was stirred at room temperature overnight. After concentration, the residue was passed through a short silica gel column. The eluate with 20% MeOH in CHCl3 was collected and concentrated. The residue was dissolved in MeOH (2 mL) and concentrated NH4OH (4 mL). The mixture was heated at 60 °C in a sealed tube for 11 h. After cooling, the solvent was removed under reduced pressure and the residue was purified by column chromatography over silica gel (1 × 8 cm, 20% MeOH in CHCl3) to give β-18 (15 mg, 66%) as crystals: mp 207-209 °C (crystallized from MeOH); UV (MeOH) λmax 258, 283 nm; 1H NMR (DMSO-d6) δ 7.77 (1H, s, H-8), 6.63 (2H, br s, NH2), 5.76 (2H, br s, NH2), 5.56 (1H, d, 3′-OH, J ) 6.4 Hz), 4.91 (1H, t, 5′-OH, J ) 4.4 Hz), 4.60 (1H, dt, H-2′, J ) 7.3, 10.3 Hz), 4.37-4.31 (1H, m, H-3′), 3.88 (1H, dt, H-5′a, J ) 4.4, 10.7 Hz), 3.46-3.38 (1H, m, H-5′b), 3.30-3.19 (2H, m, H-1′a, H-4′), 2.98 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz); FAB-MS m/z 283 (M+ + H). Anal. Calcd for C10H14N6O2S‚0.75MeOH: C, 42.15; H, 5.59; N, 27.43. Found: C, 42.35; H, 5.49; N, 27.31 (2S)-1,4-Anhydro-2-deoxy-2-(guanin-9-yl)-4-thio-D-arabitol (β-19). A mixture of β-17 (233 mg, 0.40 mmol) and NH4F‚HF (276 mg, 4,8 mmol) in DMF (5 mL) was stirred at room temperature overnight. After concentration, the residue was passed through a short silica gel column. The eluate with 20% MeOH in CHCl3 was collected and concentrated. The residue was dissolved in TFA-H2O (5 mL, 3:1) and stirred for

Iso-4′-thionucleosides 40 h at room temperature. After the solvent was removed under reduced pressure, the residue was dissolved in MeOH (10 mL) and concentrated NH4OH (20 mL). The mixture was heated at 80 °C in a sealed tube for 5 h. After cooling, the solvent was removed under reduced pressure and the residue was applied to a column of adsorption resin (8 mL, Sepabeads SP206, Mitsubishi Chemical Corp., Tokyo, Japan). The eluate of 10% aqueous EtOH was collected and concentrated to give β-19 (91 mg, 80%) as crystals: mp >250 °C (dec, crystallized from H2O); UV (MeOH) λmax 256 nm; 1H NMR (DMSO-d6) δ 10.60 (1H, br s, NH), 7.78 (1H, s, H-8), 6.45 (2H, br s, NH2), 5.58 (1H, d, 3′-OH, J ) 5.8 Hz), 4.92 (1H, br s, 5′-OH), 4.59 (1H, dt, H-2′, J ) 7.3, 10.3 Hz), 4.32-4.26 (1H, m, H-3′), 3.88 (1H, br d, H-5′a, J ) 10.7 Hz), 3.46-3.40 (1H, m, H-5′b), 3.233.17 (2H, m, H-1′a, H-4′), 2.97 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz); FAB-MS m/z 284 (M+ + H). Anal. Calcd for C10H13N5O3S‚ 0.9H2O: C, 40.10; H, 5.01; N, 23.38. Found: C, 40.33; H, 5.31; N, 23.12. (2S)-1,4-Anhydro-2-(N3-benzoyl-5-fluorouracil-1-yl)-3O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-Darabitol (20a) and (2S)-1,4-Anhydro-2-O-(N3-benzoyl-5fluoropyrimidin-4-on-2-yl)-3-O-benzyl-5-O-(tertbutyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (21a). A solution of DEAD (2.9 mL, 40% toluene solution, 6.3 mmol) was added to a mixture of 13 (1.91 g, 4.0 mmol), N 3-benzoyl5-fluorouracil (1.40 g, 6.0 mmol), and triphenylphosphine (3.14 g, 4.0 mmol) in CH3CN (64 mL) at 0 °C and stirred for 1 h at 70 °C. After cooling, the reaction was quenched by addition of EtOH. The solvent was evaporated under reduced pressure, and the residue was purified by column chromatography over silica gel (3.6 × 20 cm, 1% MeOH in CHCl3, and then 3.6 × 20 cm, 10-20% AcOEt in hexane) to give less polar 21a (213 mg, 8%) and more polar 20a (497 mg, 18%) as an amorphous foam, respectively. Data for 20a: 1H NMR (CDCl3) δ 7.87 (2H, dd, Ar H, J ) 1.5, 8.8 Hz), 7.70-7.64 (5H, m, Ar H), 7.49-7.18 (14H, m, Ar H, H-6), 4.98-4.92 (1H, m, H-2′), 4.63 (1H, d, PhCH, J ) 11.7 Hz), 4.42 (1H, d, PhCH, J ) 11.7 Hz), 4.28 (1H, dd, H-3′, J ) 5.9, 6.9 Hz), 3.87 (1H, dd, H-5′a, J ) 5.9, 10.7 Hz), 3.81 (1H, dd, H-5′b, J ) 5.9, 10.7 Hz), 3.53 (1H, q, H-4′, J ) 5.9 Hz), 3.08 (1H, dd, H-1′a, J ) 7.3, 11.7 Hz), 3.00 (1H, dd, H-1′b, J ) 8.3, 11.7 Hz), 1.08 (9H, s, t-Bu); FAB-MS m/z 695 (M+ + H). Anal. Calcd for C39H39N2O5SSiF‚0.75H2O: C, 66.12; H, 5.76; N, 3.95. Found: C, 66.18; H, 5.66; N, 3.96. Data for 21a: 1H NMR (CDCl3) δ 8.30-8.12 (3H, m, Ar H, H-6), 7.71-7.21 (18H, m, Ar H), 5.73-5.70 (1H, m, H-2′), 4.68 (1H, d, PhCH, J ) 12.2 Hz), 4.64 (1H, d, PhCH, J ) 12.2 Hz), 4.47 (1H, t, H-3′, J ) 2.9 Hz), 3.87 (1H, dd, H-5′a, J ) 8.3, 10.3 Hz), 3.71 (1H, dd, H-5′b, J ) 3.4, 10.3 Hz), 3.62-3.58 (1H, m, H-4′), 3.42 (1H, dd, H-1′a, J ) 4.9, 12.2 Hz), 3.04 (1H, dd, H-1′b, J ) 3.9, 12.2 Hz), 1.03 (9H, s, t-Bu); FAB-MS m/z 695 (M+ + H). Anal. Calcd for C39H39N2O5SSiF‚0.5hexane: C, 68.36; H, 6.28; N, 3.80. Found: C, 68.34; H, 6.42; N, 3.68. (2S)-1,4-Anhydro-2-(N3-benzoyl-5-methyluracil-1-yl)-3O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-Darabitol (20b) and (2S)-1,4-Anhydro-2-O-(N3-benzoyl-5methylpyrimidin-4-on-2-yl)-3-O-benzyl-5-O-(tertbutyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (21b). Compound 13 (720 mg, 1.5 mmol) was converted as described for the synthesis of 20a to give a mixture of 20b and 21b (367 mg, 36%, 20b/21b ) 1.3) as an amorphous foam: 1H NMR (CDCl3) δ 7.88-7.06 (21H, m, Ar H, H-6), 5.56-5.53 (0.43H, m, H-2′), 4.96-4.90 (0.57H, m, H-2′), 4.68 (0.43H, d, PhCH, J ) 12.2 Hz), 4.62 (0.43H, d, PhCH, J ) 12.2 Hz), 4.60 (0.57H, d, PhCH, J ) 12.2 Hz), 4.43 (0.57H, d, PhCH, J ) 12.2 Hz), 4.37 (0.57H, dd, H-3′, J ) 5.9, 7.3 Hz), 4.32 (0.43H, t, H-3′, J ) 3.4 Hz), 3.88 (0.57H, dd, H-5′a, J ) 5.9, 10.7 Hz), 3.79 (0.57H, dd, H-5′b, J ) 5.9, 10.7 Hz), 3.74-3.66 (0.86H, m, H-5′a,b), 3.63-3.59 (0.43H, m, H-4′), 3.52 (0.57H, q, H-4′, J ) 5.9 Hz), 3.55 (0.43H, dd, H-1′a, J ) 4.9, 12.2 Hz), 3.12 (0.57H, dd, H-1′a, J ) 9.3, 11.2 Hz), 3.04 (0.57H, dd, H-1′b, J ) 7.3, 11.2 Hz), 2.95 (0.43H, dd, H-1′b, J ) 3.4, 12.2 Hz), 1.96 (1.29H, d, 5-Me, J ) 1.0 Hz), 1.83 (1.71H, s, 5-Me), 1.07 (5.13H, s, t-Bu), 1.03 (3.87H, s, t-Bu); FAB-MS m/z 691 (M+ + H).

J. Org. Chem., Vol. 63, No. 20, 1998 6897 (2S)-1,4-Anhydro-2-(N3-benzoyl-5-(E)-(bromovinyl)uracil-1-yl)-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy4-thio-D-arabitol (20c) and (2S)-1,4-Anhydro-2-O-(N3benzoyl-5-(E)-(bromovinyl)pyrimidin-4-on-2-yl)-3-Obenzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-Darabitol (21c). Compound 13 (960 mg, 2.0 mmol) was converted as described for the synthesis of 20a to give a mixture of 20c and 21c (630 mg, 40%, 20c/21c ) 1.5) as an amorphous foam: 1H NMR (CDCl3) δ 7.88-7.16 (22H, m, Ar H, H-6, 5-vinyl H), 6.79 (0.4H, d, 5-vinyl H, J ) 13.2 Hz), 6.45 (0.6H, d, 5-vinyl H, J ) 13.7 Hz), 5.60-5.55 (0.4H, m, H-2′), 5.00-4.93 (0.6H, m, H-2′), 4.69 (0.4H, d, PhCH, J ) 11.7 Hz), 4.61 (1H, d, PhCH, J ) 11.7 Hz), 4.42 (0.6H, d, PhCH, J ) 11.7 Hz), 4.36-4.31 (1H, m, H-3′), 3.87 (0.6H, dd, H-5′a, J ) 5.9, 10.7 Hz), 3.81 (0.6H, dd, H-5′b, J ) 5.9, 10.7 Hz), 3.713.51 (1.8H, m, H-5′a,b, H-4′×2), 3.36 (0.4H, dd, H-1′a, J ) 4.9, 12.2 Hz), 3.08 (1.2H, d, H-1′a,b, J ) 8.3 Hz), 2.95 (0.4H, dd, H-1′b, J ) 3.4, 12.2 Hz), 1.08 (5.4H, s, t-Bu), 1.04 (3.6H, s, t-Bu); FAB-MS m/z 781, 783 (M+ + H). (2S)-1,4-Anhydro-2-(N3-benzoyluracil-1-yl)-3-O-benzyl5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (20d) and (2S)-1,4-Anhydro-2-O-(4-(N3-benzoyluracil-1yl)pyrimidin-2-yl)-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (22). Compound 13 (1.91 g, 4.0 mmol) was converted as described for the synthesis of 20a to give a mixture of 20d and 22 (1.10 g, 39%, 20d/22 ) 1.2) as an amorphous foam: 1H NMR (CDCl3) δ 8.54 (0.45H, d, H-6, J ) 5.4 Hz), 8.44 (0.45H, d, H-6′′, J ) 8.3 Hz), 7.97-7.17 (21H, m, Ar H, H-6, H-5), 6.02 (0.45H, d, H-5′′, J ) 8.3 Hz), 5.715.68 (0.45H, m, H-2′), 5.65 (0.55H, d, H-5, J ) 7.8 Hz), 4.954.89 (0.55H, m, H-2′), 4.72 (0.45H, d, PhCH, J ) 11.7 Hz), 4.67 (0.45H, d, PhCH, J ) 11.7 Hz), 4.59 (0.55H, d, PhCH, J ) 11.7 Hz), 4.48-4.45 (1H, m, PhCH, H-3′), 4.37 (0.55H, dd, H-3′, J ) 5.4, 6.9 Hz), 3.95-3.49 (3H, m, H-5′a,b × 2, H-4′ × 2), 3.40 (0.45H, dd, H-1′a, J ) 5.4, 11.7 Hz), 3.12-3.09 (1.1H, m, H-1′a,b), 3.05 (0.45H, dd, H-1′b, J ) 4.4, 11.7 Hz), 1.06 (4.95H, s, t-Bu), 1.02 (4.05H, s, t-Bu); FAB-MS m/z 677 (M+ + H) and 771 (M+ + H). (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-2-(5-fluorouracil-1-yl)-4-thio-D-arabitol (23a). To a solution of 20a (490 mg, 0.71 mmol) in MeOH-THF (18 mL, 4:5) was added concentrated NH4OH (9 mL) and stirred for 2 h at room temperature. After the solvent was evaporated under reduced pressure, the concentrated residue was purified by column chromatography over silica gel (2.2 × 18 cm, 2030% AcOEt in hexane) to give 23a (379 mg, 91%) as an amorphous foam: 1H NMR (CDCl3) δ 8.49-8.40 (1H, br, NH), 7.68 (4H, dd, Ar H, J ) 1.5, 7.8 Hz), 7.48-7.38 (7H, m, Ar H), 7.28-7.24 (2H, m, Ar H), 7.17-7.14 (3H, m, Ar H, H-6), 4.914.85 (1H, m, H-2′), 4.62 (1H, d, PhCH, J ) 12.2 Hz), 4.40 (1H, d, PhCH, J ) 12.2 Hz), 4.26 (1H, dd, H-3′, J ) 5.4, 7.3 Hz), 3.84 (2H, d, H-5′a,b, J ) 5.4 Hz), 3.53 (1H, q, H-4′, J ) 5.4 Hz), 3.05 (1H, dd, H-1′a, J ) 7.8, 11.2 Hz), 2.96 (1H, dd, H-1′b, J ) 8.8, 11.2 Hz), 1.10 (9H, s, t-Bu); FAB-MS m/z 591 (M+ + H). Anal. Calcd for C32H35N2O4SSiF‚1.25AcOEt: C, 63.40; H, 6.47; N, 4.00. Found: C, 63.18; H, 6.58; N, 3.99. (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-2-(5-methyluracil-1-yl)-4-thio- D-arabitol (23b) and (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-deoxy-2-O-(5-methylpyrimidin-4(3H)-on2-yl)-4-thio-D-arabitol (24b). A mixture of compound 20b and 21b (360 mg, 0.52 mmol) was converted as described for the synthesis of 23a to give less polar 24b (119 mg, 39%) and more polar 23b (141 mg, 46%) as an amorphous foam, respectively. Data for 23b: 1H NMR (CDCl3) δ 8.30 (1H, br s, NH), 7.68 (4H, dd, Ar H, J ) 1.5, 8.3 Hz), 7.47-7.37 (6H, m, Ar H), 7.257.23 (3H, m, Ar H), 7.13-7.11 (2H, m, Ar H), 6.91 (1H, d, H-6, J ) 1.0 Hz), 4.92-4.85 (1H, m, H-2′), 4.58 (1H, d, PhCH, J ) 12.2 Hz), 4.39 (1H, d, PhCH, J ) 12.2 Hz), 4.34 (1H, dd, H-3′, J ) 5.9, 7.8 Hz), 3.87 (1H, dd, H-5′a, J ) 5.9, 10.3 Hz), 3.82 (1H, dd, H-5′b, J ) 5.9, 10.3 Hz), 3.52 (1H, q, H-4′, J ) 5.9 Hz), 3.08 (1H, dd, H-1′a, J ) 9.3, 11.2 Hz), 3.00 (1H, dd, H-1′b, J ) 7.3, 11.2 Hz), 1.78 (3H, d, 5-Me, J ) 1.0 Hz), 1.09 (9H, s,

6898 J. Org. Chem., Vol. 63, No. 20, 1998 t-Bu); FAB-MS m/z 587 (M+ + H). Anal. Calcd for C33H38N2O4SSi: C, 67.54; H, 6.53; N, 4.77. Found: C, 67.27; H, 6.65; N, 4.50. Data for 24b: 1H NMR (CDCl3) δ 9.57 (1H, br s, NH), 7.657.61 (4H, m, Ar H), 7.50 (1H, s, H-6), 7.46-7.27 (11H, m, Ar H), 5.55-5.52 (1H, m, H-2′), 4.68 (1H, d, PhCH, J ) 12.2 Hz), 4.64 (1H, d, PhCH, J ) 12.2 Hz), 4.31 (1H, t, H-3′, J ) 3.4 Hz), 3.75 (1H, dd, H-5′a, J ) 8.3, 10.7 Hz), 3.69 (1H, dd, H-5′b, J ) 5.9, 10.7 Hz), 3.59 (1H, ddd, H-4′, J ) 3.4, 5.9, 8.3 Hz), 3.36 (1H, dd, H-1′a, J ) 4.9, 12.2 Hz), 2.95 (1H, dd, H-1′b, J ) 3.9, 12.2 Hz), 1.92 (3H, s, 5-Me), 1.03 (9H, s, t-Bu); FAB-MS m/z 587 (M+ + H). Anal. Calcd for C33H38N2O4SSi: C, 67.54; H, 6.53; N, 4.77. Found: C, 67.51; H, 6.56; N, 4.53. (2S)-1,4-Anhydro-3-O-benzyl-2-(5-(E)-(bromovinyl)uracil-1-yl)-5-O-(tert-butyldiphenylsilyl)-2-deoxy-4-thio-Darabitol (23c) and (2S)-1,4-Anhydro-3-O-benzyl-2-O-(5(E)-(bromovinyl)pyrimidin-4(3H)-on-2-yl)-5-O-(tertbutyldiphenylsilyl)-2-deoxy-4-thio-D-arabitol (24c). A mixture of compounds 20c and 21c (630 mg, 0.81 mmol) was converted as described for the synthesis of 23a to give less polar 24c (212 mg, 39%) and more polar 23c (324 mg, 59%) as an amorphous foam, respectively. Data for 23c: 1H NMR (CDCl3) δ 8.39 (1H, br s, NH), 7.697.67 (4H, m, Ar H), 7.48-7.38 (6H, m, Ar H), 7.33 (1H, d, 5-vinyl H, J ) 13.7 Hz), 7.26-7.22 (3H, m, Ar H), 7.13-7.10 (2H, m, Ar H), 7.03 (1H, s, H-6), 6.43 (1H, d, 5-vinyl H, J ) 13.7 Hz), 4.91-4.85 (1H, m, H-2′), 4.60 (1H, d, PhCH, J ) 12.2 Hz), 4.38 (1H, d, PhCH, J ) 12.2 Hz), 4.33 (1H, dd, H-3′, J ) 5.9, 7.3 Hz), 3.89-3.81 (2H, m, H-5′a,b), 3.52 (1H, q, H-4′, J ) 5.9 Hz), 3.07-3.02 (2H, m, H-1′a,b), 1.10 (9H, s, t-Bu); FABMS m/z 677, 679 (M+ + H). Anal. Calcd for C34H37N2O4SSiBr‚ 0.5AcOEt: C, 59.91; H, 5.73; N, 3.88. Found: C, 60.04; H, 5.99; N, 3.73. Data for 24c: 1H NMR (CDCl3) δ 9.95 (1H, br s, NH), 7.667.59 (5H, m, Ar H, H-6), 7.52 (1H, d, 5-vinyl H, J ) 13.7 Hz), 7.45-7.22 (11H, m, Ar H), 6.77 (1H, d, 5-vinyl H, J ) 13.7 Hz), 5.60-5.57 (1H, m, H-2′), 4.69 (1H, d, PhCH, J ) 11.7 Hz), 4.63 (1H, d, PhCH, J ) 11.7 Hz), 4.31 (1H, t, H-3′, J ) 2.9 Hz), 3.72 (2H, d, H-5′a,b, J ) 7.3 Hz), 3.61 (1H, dt, H-4′, J ) 2,9, 7.3 Hz), 3.36 (1H, dd, H-1′a, J ) 4.9, 11.7 Hz), 2.95 (1H, dd, H-1′b, J ) 3.9, 11.7 Hz), 1.03 (9H, s, t-Bu); FAB-MS m/z 677, 679 (M+ + H). (2S)-1,4-Anhydro-2-deoxy-2-(5-fluorouracil-1-yl)-4-thioD-arabitol (25a). A solution of BCl3 (3.5 mL of a 1 M CH2Cl2 solution, 3.5 mmol) was added slowly to a solution of 23a (372 mg, 0.63 mmol) in CH2Cl2 (13 mL) at -78 °C. After being stirred for 1 h at the same temperature, the reaction was quenched by addition of pyridine-MeOH (5 mL, 2:1). The mixture was allowed to warm to room temperature and was stirred for 1 h. After the solvents were removed under reduced pressure, the whole was extracted with CHCl3 (×2). The organic phase was washed with H2O and brine and then dried (Na2SO4). After the solvent was removed under reduced pressure, the residue was dissolved in DMF (9 mL) and NH4F‚ HF (410 mg, 7.2 mmol) was added to the solution. After the mixture was stirred at room temperature overnight, the solvent was removed under reduced pressure. The residue was purified by column chromatography over silica gel (1.5 × 12 cm, 20% MeOH in CHCl3) to give 25a (141 mg, 85%) as crystals: mp 266-268 °C (crystallized from MeOH); UV (MeOH) λmax 273 nm; 1H NMR (DMSO-d6) δ 12.10-11.55 (1H, br, NH), 8.17 (1H, d, H-6, J ) 7.3 Hz), 5.73-5.41 (1H, br, 3′OH), 5.10-4.74 (1H, br, 5′-OH), 4.69-4.62 (1H, m, H-2′), 4.03 (1H, t, H-3′, J ) 9.3 Hz), 3.87 (1H, dd, H-5′a, J ) 3.4, 10.7 Hz), 3.42-3.37 (1H, m, H-5′b), 3.14 (1H, dt, H-4′, J ) 3.4, 9.3 Hz), 2.91 (1H, t, H-1′a, J ) 10.7 Hz), 2.80 (1H, dd, H-1′b, J ) 7.3, 10.7 Hz); FAB-MS m/z 263 (M+ + H). Anal. Calcd for C9H11N2O4SF: C, 41.22; H, 4.23; N, 10.68. Found: C, 41.37; H, 4.28; N, 10.50. (2S)-1,4-Anhydro-2-deoxy-2-O-(5-fluoropyrimidin-4(3H)on-2-yl)-4-thio-D-arabitol (26a). Compound 24a (70 mg, 0.12 mmol), which was obtained by the debenzoylation of 21a, was converted as described for the synthesis of 25a to give 26a (22 mg, 71%) as a white solid: mp 169-170 °C; UV (MeOH) λmax 270 nm; 1H NMR (DMSO-d6) δ 7.82 (1H, d, H-6,

Yamada et al. J ) 3.4 Hz), 5.77-5.35 (1H, br, 3′-OH), 5.26 (1H, q, H-2′, J ) 4.9 Hz), 4.90 (1H, br s, 5′-OH), 4.12 (1H, t, H-3′, J ) 4.9 Hz), 3.71-3.68 (1H, m, H-5′a), 3.44-3.40 (1H, m, H-5′b), 3.21-3.02 (2H, m, H-1′a, H-4′), 2.81 (1H, dd, H-1′b, J ) 4.9, 11.2 Hz); FAB-MS m/z 263 (M+ + H). Anal. Calcd for C9H11N2O4SF‚ 0.25H2O: C, 40.52; H, 4.35; N, 10.50. Found: C, 40.60; H, 4.39; N, 10.39. (2S)-1,4-Anhydro-2-deoxy-2-(5-methyluracil-1-yl)-4-thioD-arabitol (25b). Compound 23b (257 mg, 0.46 mmol) was converted as described for the synthesis of 25a to give 25b (99 mg, 74%) as a white solid: mp 268-270 °C (dec); UV (MeOH) λmax 271 nm; 1H NMR (DMSO-d6) δ 11.05-11.48 (1H, br, NH), 7.63 (1H, s, H-6), 5.51 (1H, d, 3′-OH, J ) 6.4 Hz), 4.88 (1H, dd, 5′-OH, J ) 4.4, 6.3 Hz), 4.70-4.63 (1H, m, H-2′), 4.04 (1H, dt, H-3′, J ) 6.4, 10.3 Hz), 3.87 (1H, dt, H-5′a, J ) 4.4, 10.7 Hz), 3.44-3.37 (1H, m, H-5′b), 3.17-3.12 (1H, m, H-4′), 2.90 (1H, dd, H-1′a, J ) 10.3, 11.2 Hz), 2.80 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz), 1.77 (3H, s, 5-Me); FAB-MS m/z 259 (M+ + H). Anal. Calcd for C10H14N2O4S‚0.5MeOH: C, 45.97; H, 5.88; N, 10.21. Found: C, 45.92; H, 5.69; N, 10.16. (2S)-1,4-Anhydro-2-deoxy-2-O-(5-methylpyrimidin4(3H)-on-2-yl)-4-thio-D-arabitol (26b). Compound 24b (130 mg, 0.22 mmol) was converted as described for the synthesis of 25a to give 26b (43 mg, 77%) as a white solid: mp 109111 °C; UV (MeOH) λmax 271 nm; 1H NMR (DMSO-d6) δ 12.5012.10 (1H, br, NH), 7.58 (1H, s, H-6), 5.68-5.34 (1H, br, 3′OH), 5.29 (1H, q, H-2′, J ) 4.9 Hz), 4.90 (1H, br s, 5′-OH), 4.12 (1H, t, H-3′, J ) 4.9 Hz), 3.74-3.69 (1H, m, H-5′a), 3.403.34 (1H, m, H-5′b), 3.21-3.16 (2H, m, H-1′a, H-4′), 2.80 (1H, dd, H-1′b, J ) 4.9, 11.7 Hz), 1.83 (3H, s, 5-Me); FAB-MS m/z 259 (M+ + H). Anal. Calcd for C10H14N2O4S‚0.75MeOH: C, 45.73; H, 6.07; N, 9.92. Found: C, 45.48; H, 5.77; N, 10.20. (2S)-1,4-Anhydro-2-(5-(E)-(bromovinyl)uracil-1-yl)-2deoxy-4-thio-D-arabitol (25c). Compound 23c (132 mg, 0.23 mmol) was converted as described for the synthesis of 25a to give 25c (42 mg, 71%) as a white solid: mp 173-174 °C; UV (MeOH) λmax 252, 297 nm; 1H NMR (DMSO-d6) δ 11.54 (1H, br s, NH), 8.01 (1H, s, H-6), 7.26 (1H, d, 5-vinyl H, J ) 13.2 Hz), 6.84 (1H, d, 5-vinyl H, J ) 13.2 Hz), 5.58 (1H, d, 3′-OH, J ) 5.9 Hz), 4.91 (1H, t, 5′-OH, J ) 4.9 Hz), 4.69 (1H, dt, H-2′, J ) 7.3, 10.7 Hz), 4.07-4.01 (1H, m, H-3′), 3.89-3.84 (1H, m, H-5′a), 3.43-3.38 (1H, m, H-5′b), 3.15 (1H, dt, H-4′, J ) 3.4, 8.3 Hz), 2.90 (1H, t, H-1′a, J ) 10.7 Hz), 2.83 (1H, dd, H-1′b, J ) 7.3, 10.3 Hz); FAB-MS m/z 349, 351 (M+ + H). Anal. Calcd for C11H13N2O4SBr: C, 37.83; H, 3.75; N, 8.02. Found: C, 37.69; H, 3.94; N, 7.98. (2S)-1,4-Anhydro-2-O-(5-(E)-(bromovinyl)pyrimidin4(3H)-on-2-yl)-2-deoxy-4-thio-D-arabitol (26c). Compound 24c (53 mg, 0.08 mmol) was converted as described for the synthesis of 25a to give 26c (18 mg, 65%) as a white solid: mp 82-86 °C (dec); UV (MeOH) λmax 255, 302 nm; 1H NMR (DMSO-d6) δ 13.20-12.40 (1H, br, NH), 7.89 (1H, s, H-6), 7.44 (1H, d, 5-vinyl H, J ) 13.2 Hz), 6.96 (1H, d, 5-vinyl H, J ) 13.2 Hz), 5.74-5.40 (1H, br, 3′-OH), 5.35 (1H, q, H-2′, J ) 4.9 Hz), 4.91 (1H, t, 5′-OH, J ) 4.9 Hz), 4.14 (1H, t, H-3′, J ) 4.9 Hz), 3.73-3.68 (1H, m, H-5′a), 3.51-3.38 (1H, m, H-5′b), 3.213.16 (2H, m, H-1′a, H-4′), 2.83 (1H, dd, H-1′b, J ) 4.9, 11.7 Hz); FAB-MS m/z 349, 351 (M+ + H). Anal. Calcd for C11H13N2O4SBr‚0.45H2O: C, 36.98; H, 3.92; N, 7.84. Found: C, 36.69; H, 3.62; N, 7.60. (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)-2-(cytosin-1-yl)-2-deoxy-4-thio-D-arabitol (27) and (2S)-1,4-Anhydro-3-O-benzyl-5-O-(tert-butyldiphenylsilyl)2-O-(4-(cytosin-1-yl)pyrimidin-2-yl)-2-deoxy-4-thio-D-arabitol (28). To a solution of 20d and 22 (1.10 g, 1.54 mmol) in MeOH-THF (45 mL, 3:4) was added concentrated NH4OH (23 mL), and the mixture was stirred for 2 h at room temperature. After concentration, the residue was passed through a short silica gel column. The eluate with 10-50% AcOEt in hexane was collected and concentrated. The residue was dissolved in CH3CN (34 mL), and DMAP (295 mg, 2.42 mmol), TPSCl (733 mg, 2.42 mmol), and triethylamine (0.34 mL, 2.42 mmol) were added to the solution at 0 °C. After the mixture was stirred at room temperature for 2 h, concentrated NH4OH was added at 0 °C, and then the new mixture stirred for 1.5 h at room

Iso-4′-thionucleosides temperature. After the solvents were removed under reduced pressure, the residue was purified by column chromatography over silica gel (3.6 × 18 cm, 1-10% MeOH in CHCl3) to give a mixture of 27 and 28 (507 mg, 55%, 27/28 ) 2.2) as an amorphous foam: 1H NMR (CDCl3) δ 9.82-9.47 (0.62H, br, NH2), 9.27-8.88 (1.38H, br, NH2), 8.56 (0.31H, d, H-6′′, J ) 5.9 Hz), 8.36 (0.69H, d, H-6, J ) 7.8 Hz), 7.94 (0.31H, d, H-6, J ) 5.4 Hz), 7.67-7.10 (15.31H, m, Ar H, H-5′′), 6.30 (0.69H, d, H-5, J ) 7.8 Hz), 6.28 (0.31H, d, H-5, J ) 5.4 Hz), 5.695.65 (0.31H, m, H-2′), 4.83-4.78 (0.69H, m, H-2′), 4.70 (0.31H, d, PhCH, J ) 12.2 Hz), 4.67 (0.31H, d, PhCH, J ) 12.2 Hz), 4.57 (0.69H, d, PhCH, J ) 12.2 Hz), 4.45 (0.31H, t, H-3′, J ) 3.9 Hz), 4.39 (0.69H, d, PhCH, J ) 12.2 Hz), 4.36 (0.69H, t, H-3′, J ) 6.8 Hz), 3.91 (0.31H, dd, H-5′a, J ) 7.8, 10.3 Hz), 3.85-3.74 (1.69H, m, H-5′a,b, H-5′b), 3.59 (0.31H, dt, H-4′, J ) 3.9, 10.3 Hz), 3.54-3.49 (0.69H, m, H-4′), 3.52 (0.31H, dd, H-1′a, J ) 5.9, 11.7 Hz), 3.38 (0.69H, dd, H-1′a, J ) 5.4, 11.7 Hz), 3.14-3.00 (1H, m, H-1′b×2), 1.07 (9H, s, t-Bu); FAB-MS m/z 572 (M+ + H) and 666 (M+ + H). (2S)-1,4-Anhydro-5-O-(tert-butyldiphenylsilyl)-2-(cytosin-1-yl)-2-deoxy-4-thio-D-arabitol (29) and (2S)-1,4Anhydro-5-O-(tert-butyldiphenylsilyl)-2-O-[4-(cytosin-1yl)pyrimidin-2-yl]-2-deoxy-4-thio-D-arabitol (30). To a solution of 27 and 28 (500 mg, 0.83 mmol) in CH2Cl2 (16 mL) was added slowly a solution of BCl3 (5.3 mL of a 1 M CH2Cl2 solution, 5.3 mmol) at -78 °C. After being stirred for 1.5 h at the same temperature, the reaction was quenched by addition of pyridine-MeOH (5.5 mL, 2:1). The mixture was allowed to warm to room temperature and was stirred for 1 h. After the most of organic solvents were removed under reduced pressure, the whole was extracted with CHCl3 (×2). The organic phase was washed with H2O and brine and then dried (Na2SO4). After the solvent was evaporated under reduced pressure, the concentrated residue was purified by column chromatography over silica gel (2.8 × 20 cm, 1-10% MeOH in CHCl3, and then 2.8 × 5 cm, AcOEt) to give less polar 30 (104 mg, 22%) and more polar 29 (256 mg, 53%) as an amorphous foam, respectively. Data for 29: 1H NMR (CDCl3 + D2O) δ 7.69-7.62 (4H, m, Ar H), 7.41-7.31 (7H, m, Ar H), 5.99 (1H, d, H-5, J ) 7.8 Hz), 4.95-4.88 (1H, m, H-2′), 4.21 (1H, t, H-3′, J ) 8.8 Hz), 4.02 (1H, dd, H-5′a, J ) 4.9, 10.3 Hz), 3.82 (1H, dd, H-5′b, J ) 7.3, 10.3 Hz), 3.55-3.50 (1H, m, H-4′), 2.97 (1H, dd, H-1′a, J ) 7.8, 10.3 Hz), 2.76 (1H, t, H-1′b, J ) 10.3 Hz), 1.04 (9H, s, t-Bu); FAB-MS m/z 482 (M+ + H). Anal. Calcd for C25H31N3O3SSi‚0.7H2O: C, 60.75; H, 6.61; N, 8.50. Found: C, 60.72; H, 6.41; N, 8.35. Data for 30: 1H NMR (CDCl3) δ 9.46-8.84 (2H, br, NH2), 8.52-8.42 (2H, m, H-6, H-6′′), 7.71 (1H, d, H-5, J ) 5.4 Hz), 7.68-7.65 (4H, m, Ar H), 7.43-7.26 (6H, m, Ar H), 5.58 (1H, d, H-5′′, J ) 7.3 Hz), 5.57-5.52 (1H, m, H-2′), 4.44 (1H, t, H-3′, J ) 6.8 Hz), 3.96 (1H, dd, H-5′a, J ) 6.8, 10.3 Hz), 3.84 (1H, dd, H-5′b, J ) 6.8, 10.3 Hz), 3.51 (1H, q, H-4′, J ) 3.5 Hz), 3.32 (1H, dd, H-1′a, J ) 6.8, 10.7 Hz), 2.92 (1H, dd, H-1′b, J )

J. Org. Chem., Vol. 63, No. 20, 1998 6899 7.8, 10.7 Hz), 1.04 (9H, s, t-Bu); FAB-MS m/z 576 (M+ + H). Anal. Calcd for C29H33N5O4SSi‚0.5AcOEt: C, 60.07; H, 6.02; N, 11.30. Found: C, 59.78; H, 6.05; N, 11.25. (2S)-1,4-Anhydro-2-(cytosin-1-yl)-2-deoxy-4-thio-D-arabitol (31). A mixture of 29 (234 mg, 0.50 mmol) and NH4F‚ HF (342 mg, 6.00 mmol) in DMF (7.6 mL) was stirred at room temperature overnight. After concentration, the residue was purified by column chromatography over silica gel (1.5 × 12 cm, 10-20% MeOH in CHCl3) to give 31 (84 mg, 69%) as crystals: mp 239-241 °C (crystallized from MeOH); UV (MeOH) λmax 276 nm; 1H NMR (DMSO-d6) δ 7.60 (1H, d, H-6, J ) 7.3 Hz), 7.05 (1H, br s, NH), 7.00 (1H, br s, NH), 5.67 (1H, d, H-5, J ) 7.3 Hz), 5.38 (1H, d, 3′-OH, J ) 6.8 Hz), 4.85 (1H, dd, 5′-OH, J ) 4.4, 6.4 Hz), 4.63 (1H, dt, H-2′, J ) 7.8, 10.7 Hz), 4.12-4.06 (1H, m, H-3′), 3.86 (1H, dt, H-5′a, J ) 4.4, 10.3 Hz), 3.39 (1H, ddd, H-5′b, J ) 6.4, 8.3, 10.3 Hz), 3.183.12 (1H, m, H-4′), 2.85 (1H, t, H-1′a, J ) 10.7 Hz), 2.80 (1H, dd, H-1′b, J ) 7.8, 10.7 Hz); FAB-MS m/z 244 (M+ + H). Anal. Calcd for C9H13N3O3S: C, 44.43; H, 5.39; N, 17.27. Found: C, 44.23; H, 5.36; N, 17.03. (2S)-1,4-Anhydro-2-O-(4-(cytosin-1-yl)pyrimidin-2-yl)2-deoxy-4-thio-D-arabitol (32). Compound 30 (85.4 mg, 0.15 mmol) was converted as described for the synthesis of 31 to give 33 (39.8 mg, 79%) as a white solid: mp 145 °C (dec); UV (MeOH) λmax 253, 300 nm; 1H NMR (DMSO-d6) δ 8.60 (1H, d, H-6, J ) 5.4 Hz), 8.29 (1H, d, H-6′′, J ) 7.8 Hz), 7.80 (1H, d, H-5, J ) 5.4 Hz), 7.70 (1H, br s, NH), 7.66 (1H, br s, NH), 5.99 (1H, d, H-5′′, J ) 7.8 Hz), 5.54 (1H, d, 3′-OH, J ) 4.9 Hz), 5.35 (1H, q, H-2′, J ) 4.9 Hz), 4.91 (1H, t, 5′-OH, J ) 5.4 Hz), 4.17 (1H, q, H-3′, J ) 4.9 Hz), 3.77-3.72 (1H, m, H-5′a), 3.43-3.38 (1H, m, H-5′b), 3.28-3.18 (2H, m, H-4′, H-1′a), 2.83 (1H, dd, H-1′b, J ) 4.9, 11.2 Hz); 13C NMR (DMSO-d6-D2O) δ 166.24 (C-4′′), 164.30 (C-2), 161.40 (C-6), 160.25 (C-4), 155.00 (C-2′′), 142.35 (C-6′′), 110.81 (C-5), 97.64 (C-5′′), 83.41 (C-2′), 76.89 (C-3′), 64.13 (C-5′), 53.68 (C-4′), 31.69 (C-1′); FAB-MS m/z 338 (M+ + H). Anal. Calcd for C13H15N5O4S‚1.0H2O: C, 43.94; H, 4.82; N, 19.71. Found: C, 43.76; H, 4.32; N, 19.44.

Acknowledgment. The authors are grateful to Professor A. Matsuda, Hokkaido University, for his valuable discussions and Dr. K. Kodama, Yamasa Corp., for his continuing interest and encouragement. The authors also acknowledge Mr. M. Morozumi and Dr. K. Kondo, Yamasa Corp., for their helpful discussions. Supporting Information Available: Copies of 1H and 13C NMR, HMBC, and NOE spectral charts of 32 (4 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information. JO980667S